Results 81 to 90 of about 16,591 (206)

Liquid biopsy in genitourinary oncology: Current clinical applications and future prospects across prostate, bladder, and renal cancers

UroPrecision, EarlyView.
Abstract Liquid biopsy has emerged as a transformative approach in oncology, providing minimally invasive access to tumor‐derived biomarkers with applications across diagnosis, prognosis, therapeutic guidance, and disease monitoring. This literature review synthesizes evidence from 125 studies evaluating circulating tumor DNA, circulating tumor cells ...
Kirolos Eskandar
wiley   +1 more source

Identification of genetically predicted protein biomarkers and drug targets for prostate cancer via Mendelian randomization

VIEW, EarlyView.
Prostate cancer, a leading cause of cancer in men globally, urgently requires improved diagnostic and treatment strategies. This study analyzed large genetic datasets and identified five key proteins (THBD, DST, IFI27L2, OSBPL10, PPP1R14A) that either increase or decrease cancer risk, while also exploring their roles in immune response and potential ...
Maoping Cai, Tianming Peng, Zhiyue Xie, Chuqian Zhen, Chen Yao, Nan Peng, Qianyi Li, Yuzhong Yu, Jiming Bao, Xian‐Lu Song, Mingkun Chen, Shan‐Chao Zhao   +11 more
wiley   +1 more source

Utility of SUVmax on Primary Staging 68Ga‐PSMA PET in Determining Metastatic Status of Prostate Cancer

Journal of Medical Imaging and Radiation Oncology, EarlyView.
ABSTRACT Introduction 68Ga prostate‐specific membrane antigen (PSMA) has been shown to have prognostic value in detecting PSMA expressing metastasis from prostate cancer, but inevitably, there are cases in which suspected metastases demonstrate equivocal uptake.
Geoffrey Liu, Shane Lee, Kabir Ahmad
wiley   +1 more source

Studies on the mechanisms of sorafenib-induced cell death [PDF]

, 2014
In 2008, 26% of all deaths were cancer-related, making this group of diseases the second leading cause of death in the EU countries. Derailment of tyrosine kinase signaling is one important pre-requisite towards tumorigenesis.
Kharaziha, Pedram
core   +1 more source

Management of Advanced Prostate Cancer in the Asia‐Pacific Region: Summary of the Asia‐Pacific Advanced Prostate Cancer Symposium 2025

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Summary of the Asia Pacific Advanced Prostate Cancer Symposium 2025, showing disciplines and diversity of participants, discussion topics (high‐risk localized/locally advanced prostate cancer; PSA persistence and recurrence; radioligand therapy; genetics and genomics; bone protection and other aspects of supportive care), key themes, and high‐level ...
Edmund Chiong, Renu Eapen, Nicholas Buchan, Kenneth Chen, Lukman Hakim, Agus Rizal Hamid, Jae‐Young Joung, Ravindran Kanesvaran, Makarand Khochikar, Jason Letran, Bannakij Lojanapiwat, Indranil Mallick, Chi Fai Ng, Pei Ing Ngam, Teng Aik Ong, Jacob Pang, Darren M. C. Poon, Natasha Roberts, Marniza Saad, Shinichi Sakamoto, Jeremy Tey, Sue Ping Thang, Poh Choo Toh, Levent Türkeri, Nguyễn Tuấn Vinh, Alvin Wong, Yao Zhu, ANZUP Cancer Trials Group, Ian D. Davis   +28 more
wiley   +1 more source

Synergistic RU486 and olaparib therapy enhances apoptosis in endometriosis by simultaneously targeting hormonal signalling and DNA repair

British Journal of Pharmacology, EarlyView.
Background and Purpose Endometriosis is a chronic, hormone‐dependent disorder characterized by ectopic implantation of endometrial tissue, often accompanied by pain and infertility. Although the progesterone receptor modulator RU486 is effective for pain relief, its impact on lesion regression is limited, possibly due to apoptosis resistance and ...
Yujie Peng, Meng Zhang, Libo Zhu, Wenqiang Qian, Jingjing Yan, Huidi Jiang, Yu Xin, Ying Zhang, Dongli Sun, Weidong Fei, Mengdan Zhao   +10 more
wiley   +1 more source

A case of double‐negative prostate cancer with BRCA2 mutation and high tumor mutation burden treated sequentially with olaparib and pembrolizumab

IJU Case Reports
Introduction Double‐negative prostate cancer, an androgen receptor–independent prostate cancer without features of neuroendocrine tumors, is refractory to treatment but could be an ideal candidate for individualized treatment.
Hiroki Tanaka, Soichiro Yoshida, Satoru Aoyama, Sadakatsu Ikeda, Junko Kunieda, Kenichi Ohashi, Shohei Fukuda, Yuma Waseda, Hajime Tanaka, Yasuhisa Fujii   +9 more
doaj   +1 more source

The Role of Prostate‐Specific Antigen (PSA) and PSA Kinetics in the Management of Advanced Prostate Cancer [PDF]

, 2016
Prostate‐specific antigen (PSA) plays an important role in the diagnosis and management of prostate cancer. The utility of PSA has been extended to a number of parameters which may guide clinical decision‐making in subsequent treatment. This book chapter
Teoh, Jeremy, Yiu, Ming‐Kwong
core   +1 more source

Compound Library Screening Identified Cladribine as a Novel Radiosensitizer for Prostate Cancer

Cancer Science, EarlyView.
The combination of cladribine and irradiation significantly suppressed the growth of DU145‐derived tumors compared with the DMSO plus irradiation group in the mouse model. In addition, it also elevated the percentage of γH2AX‐positive cells after irradiation.
Toshiki Oka, Koji Hatano, Shohei Katsuki, Tomohiro Kanaki, Shunsuke Inoguchi, Masaru Tani, Akihiro Yoshimura, Yuki Horibe, Yutong Liu, Nesrine Sassi, Yohei Okuda, Akinaru Yamamoto, Toshihiro Uemura, Gaku Yamamichi, Yu Ishizuya, Takuji Hayashi, Yoshiyuki Yamamoto, Taigo Kato, Atsunari Kawashima, Keisuke Tamari, Bangzhong Lin, Akiyoshi Tani, Kazutake Tsujikawa, Yutaka Takahashi, Kazuhiko Ogawa, Shawn E. Lupold, Norio Nonomura   +26 more
wiley   +1 more source

Roles of TIF1β in Leukemic Stem Cell Through SETDB1‐Dependent and Independent Mechanisms

Cancer Science, EarlyView.
In leukemic stem cell, BCR::ABL cooperates with TIF1β to open chromatin at oncogenes and close chromatin at differentiation regulators, driving leukemic reprogramming. In TIF1β‐deficient stem cell, the loss of TIF1β inverts this balance, showing closed chromatin at oncogenes and open chromatin at differentiation regulators.
Mariko Morii, Sho Kubota, Goro Sashida
wiley   +1 more source